Submitted by Anonymous (not verified) on 10 November 2023 - 14:32
Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, Multiple Sclerosis, Date of authorisation: 08/01/2018, Revision: 18, Status: Authorised
Source: